Loading…
← CockpitCompetitor Analysis › 368A.T Kitazato CorporationOpen in the cockpit ↗

Kitazato Corporation368A.TCompetitor analysis, valuation and peers

Japan · JPY·Health Care›Pharmaceuticals: Major
Momentum weak 34
Mkt cap
$317M
US dollars, full cap
Free float
40%
of shares outstanding
$/day
$1.34M
20-day average traded
Fwd P/E
12.2×
forward earnings
ROIC−WACC
+56.4 pp
WACC 5.1%
Hurdle
-22 pp
Req g minus delivered
Next earnings
79 days
5 Feb 2027
Close · JPY¥1,289
1D+0.8%
1W+0.6%
1M-9.3%
3M-18.8%
6M+6.9%
YTD-17.6%
1Y-5.3%
ATR %2.7%
52w lowhigh23.9% off high

What Kitazato does

Employees: 83

Kitazato at a glance

Size Kitazato (368A.T) is a Japan Health Care company (Pharmaceuticals: Major) with a market value of $317M, the 1324th largest of 1,370 Japan companies the cockpit tracks. Shares closed at ¥1,289 on 18 Nov 2026.

Performance Over six months the shares gained 6.9%, against -22.1% for the median peer and -1.4% for the Japan market (cap-weighted) — 6th highest of 21 in its peer set.

Growth Revenue grew 9.3% over the last twelve months (peer median +2.5%); the operating margin is 52.1% (peer median -1.9%).

Valuation It trades at 12.2× forward earnings against a peer median of 24.9× (cheapest of 4).

Price implies For today's price to make sense, revenue must grow about -17% a year for seven years (Req g). Recent delivered growth is +5%, so the hurdle is -22 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 56.4 points above its cost of capital (5.1% WACC).

Next results Next results expected around 5 Feb 2027 (exchange calendar; dates can move).

Relative performance

8010012014021 May 202621 Aug 202618 Nov 2026368A.T 110Peer median 77
Six months, rebased to 100: Kitazato against the median of its 20 peers (local-currency closes).

Kitazato financials

Reported figures in JPY; fiscal year ends 2026-03-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue¥11.7B¥10.9B¥10.3B¥10.1B¥9.35B
Revenue growth—+6%+2%+8%—
Gross profit¥7.53B¥7.21B¥6.97B¥7.04B¥6.70B
EBITDA¥6.32B¥6.05B¥5.96B¥6.09B¥5.29B
Net income¥4.12B¥3.90B¥3.79B¥3.97B¥3.37B
Free cash flown/a¥3.63B¥2.63B¥4.42B¥2.05B
Capital expendituren/a¥239M¥903M¥85.0M¥80.0M
Total debt¥39.0M¥102M¥120M¥165M¥133M

Quarterly statements and history in the cockpit →

Kitazato competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%+100%+150%0%+25%+50%INOINDSWFTLABAVIR005250SECAREALEMBICLTD6005383013310021681720RLMDMYXSOLARA300086368A.T6-month return →1-month return →
Up and to the right = strong over both horizons. Kitazato is the large dot.

Fundamentals: revenue growth against valuation

-40%-20%0%+20%0×100×200×300×SECARE1875SOLARA368A.TRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Kitazato is the large dot.

Capital: growth delivered against growth the price implies

-20%0%+20%+40%+60%0%25%50%SECARE000790ALEMBICLTD3013310021681720301509MYXSOLARA300086603079368A.TGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Kitazato is the large dot.

Kitazato competitors and peer comparison

How Kitazato compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Kitazato against its 20 peers (data as of 18 Nov 2026)
Measure368A.TPeer medianRank in peer set
1-month return-9.3%-6.1%10th lowest of 21
6-month return+6.9%-22.1%6th highest of 21
Distance from 52-week high-23.9%-38.0%6th highest of 21
Revenue growth (TTM)+9.3%+2.5%6th highest of 19
Operating margin52.1%-1.9%highest of 19
Forward P/E12.2×24.9×cheapest of 4
Growth the price implies (Req g, 7 yrs)-16.8%14.3%least demanding of 12
Growth delivered (Del g)+5.4%-0.3%6th highest of 12
Hurdle (Req g minus delivered)-22.2 pp+17.6 pp2nd least demanding of 12
ROIC minus cost of capital+56.4 pp-7.7 pphighest of 18
EV / EBITDA5.8×15.8×cheapest of 7
Net debt / EBITDA-2.2×-0.6×3rd least indebted of 8

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Kitazato 368A.TJapan$317M+7%+9%52%12.2×-16.8%+5.4%
Inovio Pharmaceuticals INOUnited States$317M+37%+64%-25,954%n/an/an/a
Ind-Swift Laboratories INDSWFTLAB.NSIndia$314M+150%+66%9%n/an/an/a
Atea Pharmaceuticals AVIRUnited States$320M-5%n/an/an/an/an/a
GC Corp. 005250.KSSouth Korea$321M-45%+2%3%n/an/an/a
Swedencare SECARE.STSweden$321M-24%+3%7%24.9×6.1%+62.1%
Chengdu Huasun Technology 000790.SZChina$312M-20%-36%-57%n/a27.5%-6.4%
Foresee Pharmaceuticals 6576.TWOTaiwan$322M-12%+6%-104%n/an/an/a
Alembic ALEMBICLTD.NSIndia$309M+25%-5%26%n/a44.3%+26.7%
Beihai Gofar Chuanshan Biological 600538.SSChina$326M-39%+10%-8%n/an/an/a
Enwei Pharmaceutical 301331.SZChina$308M-20%-7%5%n/a14.0%+7.3%
Chongqing Hifuture Information Technology 002168.SZChina$326M-27%+2%-6%n/a14.3%-14.0%
Hinova Pharmaceuticals 688302.SSChina$305M-35%+251%-195%n/an/an/a
Standard Chemical & Pharmaceutical 1720.TWTaiwan$329M-1%+5%22%n/a-11.5%+10.3%
Relmada Therapeutics RLMDUnited States$305M-60%n/an/an/an/an/a
Kingchem (Liaoning) Life Science 301509.SZChina$333M-28%+3%6%n/a9.2%+6.5%
Mayne Pharma MYX.AXAustralia$333M+155%-6%-14%n/a19.0%-0.9%
BioDlink International 1875.HKHong Kong$334M-24%-51%-31%288.2×n/an/a
Solara Active Pharma Sciences SOLARA.NSIndia$334M+12%+27%8%20.7×38.3%-3.2%
Honz Pharmaceutical 300086.SZChina$299M-40%-23%-54%n/a56.0%-12.8%
Zhejiang Shengda Bio-Pharm 603079.SSChina$297M-30%-3%7%n/a4.6%-0.3%

Questions

Which companies are Kitazato's closest peers?
The cockpit's peer set: Inovio Pharmaceuticals (INO), Ind-Swift Laboratories (INDSWFTLAB.NS), Atea Pharmaceuticals (AVIR), GC Corp. (005250.KS), Swedencare (SECARE.ST), Chengdu Huasun Technology (000790.SZ), Foresee Pharmaceuticals (6576.TWO), Alembic (ALEMBICLTD.NS).
Is Kitazato expensive compared with its peers?
On forward p/e it trades at 12.2× against a peer median of 24.9×, cheapest of 4 in its peer set. For today's price to make sense, revenue must grow about -17% a year for seven years (Req g). Recent delivered growth is +5%, so the hurdle is -22 pp: the price already allows for a slowdown.
How has Kitazato stock performed?
Over six months to 18 Nov 2026 the shares returned +6.9% against -22.1% for the median peer; over one year -5.3%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.